Litvan and colleagues recently proposed the Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson’s disease (PD-MCI). These criteria were needed to overcome the heterogeneity of criteria adopted in previous studies, with a mean MCI prevalence of 27% (range, 19%–38%) reported in nondemented Parkinson’s disease (PD) patients2; MCI may already be present at the time of the clinical diagnosis of PD, with prevalence ranging from 18.9% to 36% reported in newly diagnosed drug-naive patients. n a recent study4 we examined a cohort of 121 newly diagnosed drug-naive PD patients (mean age, 66.6 +-7.3 years; mean education, 9.2 +- 4.1 years; mean disease duration, 13.9 +- 11.3 months; mean UPDRS II score, 5.2 +- 3.3; mean UPDRS III score, 16.9 +- 8.4) adopting recently proposed preliminary MCI research criteria. All patients fulfilled research diagnostic criteria for idiopathic PD; atypical parkinsonian disorders such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration and other neurological or major medical conditions were considered exclusion criteria. A 1.5T MRI was performed on all patients to evaluate radiological signs of atypical parkinsonisms, neoplastic lesions, hydrocephalus, or extensive vascular damage, and a 123IFP-CIT SPECT was performed to confirm nigrostriatal degeneration. All patients received an L-dopa challenge to evaluate acute dopaminergic treatment efficacy; only patients with a consistent (>30%) improvement in tapping test were considered eligible. Furthermore, 100 age-matched subjects enrolled from among patients’ family members served as healthy controls (HCs; mean age, 66.8 +- 6.3 years; mean education, 9.2 +- 4.2 years); these subjects were free from parkinsonism, dementia, major depression, and psychosis.

Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines.

POLETTI, MICHELE;FROSINI, DANIELA;CERAVOLO, ROBERTO;BONUCCELLI, UBALDO
2012-01-01

Abstract

Litvan and colleagues recently proposed the Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson’s disease (PD-MCI). These criteria were needed to overcome the heterogeneity of criteria adopted in previous studies, with a mean MCI prevalence of 27% (range, 19%–38%) reported in nondemented Parkinson’s disease (PD) patients2; MCI may already be present at the time of the clinical diagnosis of PD, with prevalence ranging from 18.9% to 36% reported in newly diagnosed drug-naive patients. n a recent study4 we examined a cohort of 121 newly diagnosed drug-naive PD patients (mean age, 66.6 +-7.3 years; mean education, 9.2 +- 4.1 years; mean disease duration, 13.9 +- 11.3 months; mean UPDRS II score, 5.2 +- 3.3; mean UPDRS III score, 16.9 +- 8.4) adopting recently proposed preliminary MCI research criteria. All patients fulfilled research diagnostic criteria for idiopathic PD; atypical parkinsonian disorders such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration and other neurological or major medical conditions were considered exclusion criteria. A 1.5T MRI was performed on all patients to evaluate radiological signs of atypical parkinsonisms, neoplastic lesions, hydrocephalus, or extensive vascular damage, and a 123IFP-CIT SPECT was performed to confirm nigrostriatal degeneration. All patients received an L-dopa challenge to evaluate acute dopaminergic treatment efficacy; only patients with a consistent (>30%) improvement in tapping test were considered eligible. Furthermore, 100 age-matched subjects enrolled from among patients’ family members served as healthy controls (HCs; mean age, 66.8 +- 6.3 years; mean education, 9.2 +- 4.2 years); these subjects were free from parkinsonism, dementia, major depression, and psychosis.
2012
Poletti, Michele; Frosini, Daniela; Ceravolo, Roberto; Bonuccelli, Ubaldo
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/766865
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact